UroGen Pharma Ltd. (URGN) Operating margin 2016–2025
UroGen Pharma Ltd. (URGN) operating margin by fiscal year — reported operating income divided by reported revenue.
-113.7%FY2025 · since FY2016: 4.6% → -113.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -113.7% | -6.7 pp |
| FY2024 | -107.1% | -27.8 pp |
| FY2023 | -79.2% | +43.6 pp |
| FY2022 | -122.8% | +69.3 pp |
| FY2021 | -192.1% | +882.0 pp |
| FY2020 | -1074.2% | +607137.0 pp |
| FY2019 | -608211.1% | -601368.9 pp |
| FY2018 | -6842.2% | -6597.7 pp |
| FY2017 | -244.5% | -249.1 pp |
| FY2016 | 4.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice